Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Spicer, M. Harries, P. Ellis (2005)
Adjuvant trastuzumab for HER2-positive breast cancerThe Lancet, 366
N. Wolmark, Jiping Wang, E. Mamounas, J. Bryant, B. Fisher (2001)
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.Journal of the National Cancer Institute. Monographs, 30
S. Loi, S. Michiels, D. Lambrechts, D. Fumagalli, B. Claes, P. Kellokumpu-Lehtinen, P. Bono, V. Kataja, M. Piccart, H. Joensuu, C. Sotiriou (2013)
Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast CancerJNCI Journal of the National Cancer Institute, 105
E. Jung, L. Santarpia, Ju-Yeon Kim, F. Esteva, E. Moretti, A. Buzdar, A. Leo, X. Le, R. Bast, Soon‐Tae Park, L. Pusztai, G. Calin (2012)
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patientsCancer, 118
M. Piccart-Gebhart, A. Holmes, E. Azambuja, S. Cosimo, R. Swaby, M. Untch, C. Jackisch, I. Láng, I. Smith, F. Boyle, Bing-he Xu, C. Barrios, R. Gelber, H. Eidtmann, J. Baselga (2013)
Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)Cancer Research, 73
M. Rimawi, I. Mayer, A. Forero, R. Nanda, M. Goetz, Angel Rodriguez, A. Pavlick, Tao Wang, S. Hilsenbeck, C. Gutierrez, R. Schiff, C. Osborne, Jenny Chang (2013)
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 14
A. Robidoux, G. Tang, P. Rastogi, C. Geyer, C. Azar, J. Atkins, L. Fehrenbacher, H. Bear, L. Baez-Diaz, S. Sarwar, R. Margolese, W. Farrar, A. Brufsky, H. Shibata, H. Bandos, S. Paik, J. Costantino, S. Swain, E. Mamounas, N. Wolmark (2013)
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.The Lancet. Oncology, 14 12
L. Gianni, G. Romieu, M. Lichinitser, S. Serrano, M. Mansutti, X. Pivot, P. Mariani, F. André, A. Chan, O. Lipatov, S. Chan, A. Wardley, R. Greil, N. Moore, S. Prot, C. Pallaud, V. Semiglazov (2013)
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 14
L. Kenny (2013)
18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTOThe Journal of Nuclear Medicine, 54
S. Swain, Sung-Bae Kim, Javier Cortés, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J. Ferrero, A. Schneeweiss, A. Knott, E. Clark, Graham Ross, M. Benyunes, J. Baselga (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.The Lancet. Oncology, 14 6
K. Blackwell, H. Burstein, A. Storniolo, H. Rugo, G. Sledge, G. Aktan, C. Ellis, A. Florance, S. Vukelja, J. Bischoff, J. Baselga, J. O’Shaughnessy (2012)
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
D. Slamon, W. Eiermann, N. Robert, T. Pieńkowski, Miguel Martín, M. Press, J. Mackey, J. Glaspy, A. Chan, M. Pawlicki, T. Pintér, V. Valero, Mei-Ching Liu, G. Sauter, G. Minckwitz, F. Visco, V. Bée, M. Buyse, B. Bendahmane, I. Tabah-Fisch, M. Lindsay, A. Riva, J. Crown (2011)
Adjuvant trastuzumab in HER2-positive breast cancer.The New England journal of medicine, 365 14
J. Baselga, I. Bradbury, H. Eidtmann, S. Cosimo, E. Azambuja, C. Aura, H. Gómez, P. Dinh, K. Fauria, V. Dooren, G. Aktan, A. Goldhirsch, Tsai-Wang Chang, Z. Horváth, M. Coccia-Portugal, J. Dômont, L. Tseng, G. Kunz, J. Sohn, V. Semiglazov, G. Lerzo, M. Pálácova, V. Probachai, L. Pusztai, M. Untch, R. Gelber, M. Piccart-Gebhart (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialThe Lancet, 379
G. Ismael, R. Hegg, S. Muehlbauer, D. Heinzmann, B. Lum, Sung-Bae Kim, T. Pieńkowski, M. Lichinitser, V. Semiglazov, B. Melichar, C. Jackisch (2012)
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.The Lancet. Oncology, 13 9
S. Loibl, J. Bruey, G. Minckwitz, J. Huober, Michael Press, S. Darb-Esfahani, C. Solbach, C. Denkert, H. Tesch, F. Holms, T. Fehm, K. Mehta, M. Untch (2011)
Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
V. Guarneri, A. Frassoldati, A. Bottini, K. Cagossi, G. Bisagni, S. Sarti, A. Ravaioli, L. Cavanna, G. Giardina, A. Musolino, M. Untch, L. Orlando, F. Artioli, C. Boni, D. Generali, P. Serra, M. Bagnalasta, L. Marini, F. Piacentini, R. D'amico, P. Conte (2012)
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 16
P. Cortazar, Lijun Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, S. Swain, Tatiana Prowell, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, R. Justice, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, L. Slaets, Shenghui Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, G. Minckwitz (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 384
M. Untch, P. Fasching, G. Konecny, S. Hasmüller, A. Lebeau, R. Kreienberg, O. Camara, V. Müller, A. Bois, T. Kühn, E. Stickeler, N. Harbeck, C. Höss, S. Kahlert, T. Beck, W. Fett, K. Mehta, G. Minckwitz, S. Loibl (2011)
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 25
B. Hennessy, G. Hortobagyi, R. Rouzier, H. Kuerer, N. Sneige, A. Buzdar, S. Kau, B. Fornage, A. Sahin, K. Broglio, S. Singletary, V. Valero (2005)
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 36
J. Ross, E. Slodkowska, W. Symmans, L. Pusztai, P. Ravdin, G. Hortobagyi (2009)
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.The oncologist, 14 4
L. Gianni, T. Pieńkowski, Y. Im, L. Roman, L. Tseng, Mei-Ching Liu, A. Lluch, E. Starosławska, J. Haba-Rodríguez, S. Im, J. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, G. Bianchi, T. Szado, J. Ratnayake, G. Ross, P. Valagussa (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.The Lancet. Oncology, 13 1
J. Huober, S. Loibl, M. Untch, S. Darb-Esfahani, C. Solbach, H. Tesch, F. Holms, T. Fehm, G. Minckwitz, K. Mehta, C. Denkert (2010)
Abstract PD02-06: New Molecular Biomarkers for Resistance to Trastuzumab in Primary HER2 Positive Breast Cancer — A Translational Investigation from the Neoadjuvant GeparQuattro StudyCancer Research, 70
G. Minckwitz, M. Untch, J. Blohmer, S. Costa, H. Eidtmann, P. Fasching, B. Gerber, W. Eiermann, J. Hilfrich, J. Huober, C. Jackisch, M. Kaufmann, G. Konecny, C. Denkert, V. Nekljudova, K. Mehta, S. Loibl (2012)
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
D. Slamon, B. Leyland-Jones, Steven Shak, Hank Fuchs, Virginia Paton, A. Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, M. Pegram, J. Baselga, Larry Norton (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.The New England journal of medicine, 344 11
M. Scaltriti, F. Rojo, A. Ocaña, J. Anido, M. Guzman, J. Cortés, S. Cosimo, X. Matías-Guiu, S. Cajal, J. Arribas, J. Baselga (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.Journal of the National Cancer Institute, 99 8
A. Prat, J. Baselga (2013)
Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 14
J. Hage, C. Velde, J. Julien, M. Tubiana-Hulin, Cecile Vandervelden, L. Duchateau (2001)
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 22
F. Esteva, Jing Wang, F. Lin, J. Mejia, Kai Yan, K. Altundağ, K. Altundağ, V. Valero, A. Buzdar, G. Hortobagyi, W. Symmans, L. Pusztai (2007)
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancerBreast Cancer Research : BCR, 9
C. Wild (2002)
Trastuzumab for breast cancer
A. Schneeweiss, S. Chia, T. Hickish, Vernon Harvey, A. Eniu, R. Hegg, C. Tausch, J. Seo, Y. Tsai, J. Ratnayake, V. Mcnally, G. Ross, J. Cortés (2013)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).Annals of oncology : official journal of the European Society for Medical Oncology, 24 9
J. Baselga, J. Cortés, Sung-Bae Kim, S. Im, R. Hegg, Y. Im, L. Roman, J. Pedrini, T. Pieńkowski, A. Knott, E. Clark, M. Benyunes, G. Ross, S. Swain (2012)
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.The New England journal of medicine, 366 2
B. Dave, I. Migliaccio, M. Gutiérrez, Meng-Fen Wu, G. Chamness, H. Wong, A. Narasanna, A. Chakrabarty, S. Hilsenbeck, Jian Huang, M. Rimawi, R. Schiff, C. Arteaga, C. Osborne, Jenny Chang (2011)
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 2
L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch, S. Tjulandin, M. Zambetti, F. Vázquez, M. Byakhov, M. Lichinitser, M. Climent, E. Ciruelos, B. Ojeda, M. Mansutti, Bozhok Aa, D. Magazzù, J. Steinseifer, P. Valagussa, J. Baselga (2013)
Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.Journal of Clinical Oncology, 31
A. Buzdar, N. Ibrahim, D. Francis, D. Booser, E. Thomas, R. Theriault, L. Pusztai, Marjorie Green, B. Arun, S. Giordano, M. Cristofanilli, D. Frye, T. Smith, K. Hunt, S. Singletary, A. Sahin, M. Ewer, T. Buchholz, D. Berry, G. Hortobagyi (2005)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 16
M. Morrow (2006)
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast CancerYearbook of Medicine, 2006
A. Buzdar, V. Suman, F. Meric-Bernstam, A. Leitch, M. Ellis, J. Boughey, G. Unzeitig, M. Royce, L. Mccall, M. Ewer, K. Hunt (2013)
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.The Lancet. Oncology, 14 13
L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch, S. Tjulandin, M. Zambetti, F. Vázquez, Mikhail Byakhow, M. Lichinitser, M. Climent, E. Ciruelos, B. Ojeda, M. Mansutti, A. Bozhok, Roberta Baronio, A. Feyereislova, C. Barton, P. Valagussa, J. Baselga (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortThe Lancet, 375
I. Witzel, S. Loibl, G. Minckwitz, C. Mundhenke, J. Huober, C. Hanusch, S. Henschen, M. Hauschild, T. Lantzsch, H. Tesch, K. Latos, M. Just, J. Hilfrich, J. Barinoff, C. Eulenburg, M. Roller, M. Untch, V. Müller (2010)
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trialBreast Cancer Research and Treatment, 123
E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer, N. Davidson, E. Tan-chiu, S. Martino, S. Paik, P. Kaufman, S. Swain, T. Pisansky, L. Fehrenbacher, L. Kutteh, V. Vogel, D. Visscher, G. Yothers, R. Jenkins, A. Brown, S. Dakhil, E. Mamounas, W. Lingle, P. Klein, J. Ingle, N. Wolmark (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.The New England journal of medicine, 353 16
L. Gianni, W. Eiermann, L. Pusztai, V. Semiglazov, B. Hoegel, A. Koehler, G. Manikhas, M. Bates, P. Valagussa, J. Baselga (2008)
Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)Journal of Clinical Oncology, 26
S. Pernas, M. Gil-Gil, M. Olza, A. Gumà, F. Climent, A. Petit, M. Pla, A. García-Tejedor, Ana López-Ojeda, C. Falo, Adela Fernandez-Otega, C. Mesía, Francisco Pérez-Martin, A. Urruticoechea, J. Germà (2012)
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practiceBreast Cancer Research and Treatment, 134
A. Musolino, N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, A. Zerbini, R. Camisa, G. Bisagni, T. Neri, A. Ardizzoni (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 11
A. Prat, C. Perou (2010)
Deconstructing the molecular portraits of breast cancerMolecular Oncology, 5
(2013)
HER2positive operable breast cancer: results of the randomised phase II CHER-LOB study
(2013)
epirubicin, and cyclophosphamide in HER-2overexpressing breast cancer
H. Bear, S. Anderson, Roy Smith, C. Geyer, E. Mamounas, B. Fisher, A. Brown, A. Robidoux, R. Margolese, M. Kahlenberg, S. Paik, A. Soran, D. Wickerham, N. Wolmark (2006)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 13
M. Giuliano, Meghana Trivedi, R. Schiff (2013)
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical ImplicationsBreast Care, 8
M. Untch, S. Loibl, J. Bischoff, H. Eidtmann, M. Kaufmann, J. Blohmer, J. Hilfrich, D. Strumberg, P. Fasching, R. Kreienberg, H. Tesch, C. Hanusch, B. Gerber, M. Rezai, C. Jackisch, J. Huober, T. Kühn, V. Nekljudova, G. Minckwitz (2012)
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.The Lancet. Oncology, 13 2
M. Scaltriti, C. Verma, M. Guzmán, J. Jiménez, J. Parra, Kim Pedersen, Derek Smith, S. Landolfi, S. Cajal, J. Arribas, J. Baselga, J. Baselga (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityOncogene, 28
H. Joensuu, P. Kellokumpu-Lehtinen, P. Bono, T. Alanko, V. Kataja, R. Asola, T. Utriainen, R. Kokko, A. Hemminki, M. Tarkkanen, T. Turpeenniemi‐Hujanen, S. Jyrkkiö, M. Flander, L. Helle, S. Ingalsuo, Kaisu Johansson, A. Jääskeläinen, M. Pajunen, Mervi Rauhala, J. Kaleva-Kerola, T. Salminen, M. Leinonen, I. Elomaa, J. Isola (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.The New England journal of medicine, 354 8
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science, 235 4785
Yoichi Nagata, K. Lan, Xiaoyan Zhou, M. Tan, F. Esteva, A. Sahin, K. Klos, Ping Li, B. Monia, Nina Nguyen, G. Hortobagyi, M. Hung, Dihua Yu (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.Cancer cell, 6 2
I. Witzel, S. Loibl, G. Minckwitz, H. Eidtmann, T. Fehm, F. Khandan, S. Schmatloch, M. Hauschild, Joachim Bischoff, Peter Fasching, Christine Mau, C. Schem, B. Rack, Ivo Meinhold-Heerlein, Cornelia Liedtke, T. Karn, J. Huober, C. Eulenburg, Yasmin Issa-Nummer, M. Untch, Volkmar Müller (2011)
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trialBritish Journal of Cancer, 107
Tatiana Prowell, R. Pazdur (2012)
Pathological complete response and accelerated drug approval in early breast cancer.The New England journal of medicine, 366 26
K. Berns, H. Horlings, B. Hennessy, M. Madiredjo, E. Hijmans, K. Beelen, S. Linn, A. González-Angulo, K. Stemke‐Hale, M. Hauptmann, R. Beijersbergen, G. Mills, M. Vijver, R. Bernards (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.Cancer cell, 12 4
Charles Geyer, J. Forster, D. Lindquist, Stephen Chan, C. Romieu, T. Pieńkowski, A. Jagiełło-Gruszfeld, J. Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, M. Campone, Neville Davidson, Mark Berger, C. Oliva, S. Rubin, S. Stein, David Cameron (2006)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.The New England journal of medicine, 355 26
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. Barrios, G. Steger, C. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. Dolci, R. Gelber (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.The New England journal of medicine, 353 16
F. Holmes, V. Espina, L. Liotta, Y. Nagarwala, M. Danso, K. McIntyre, C. Osborne, T. Anderson, L. Krekow, J. Blum, J. Pippen, A. Florance, J. Mahoney, J. O’Shaughnessy (2013)
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signalingBMC Research Notes, 6
S. Loi, S. Michiels, R. Salgado, N. Sirtaine, V. Jose, D. Fumagalli, David Brown, P. Kellokumpu-Lehtinen, P. Bono, V. Kataja, C. Desmedt, M. Piccart-Gebhart, S. Loibl, M. Untch, C. Denkert, M. Smyth, H. Joensuu, C. Sotiriou (2013)
Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC)Cancer Research, 73
S. Guiu, M. Reynier, M. Toure, Bruno Coudert (2013)
Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant TherapyJournal of Oncology, 2013
J. Staaf, M. Ringnér, J. Vallon-Christersson, G. Jönsson, P. Bendahl, K. Holm, A. Arason, Haukur Gunnarsson, C. Hegardt, B. Agnarsson, L. Luts, D. Grabau, M. Fernö, P. Malmström, O. Johannsson, N. Loman, R. Barkardottir, Å. Borg (2010)
Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 11
L. Emens, N. Davidson (2004)
Trastuzumab in breast cancer.Oncology, 18 9
Yen-chao Wang, G. Morrison, R. Gillihan, Jun Guo, R. Ward, Xiaoyong Fu, Maria Botero, N. Healy, N. Healy, S. Hilsenbeck, G. Phillips, G. Chamness, M. Rimawi, C. Osborne, R. Schiff (2011)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivationBreast Cancer Research : BCR, 13
S. Loibl, C. Denkert, A. Schneeweiss, S. Paepke, A. Lehmann, M. Rezai, D. Zahm, P. Sinn, F. Khandan, H. Eidtmann, Karel Dohnal, J. Huober, S. Loi, B. Pfitzner, P. Fasching, F. André, J. Lindner, C. Sotiriou, S. Guo, S. Gade, V. Nekljudova, M. Untch, G. Minckwitz (2013)
Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studiesCancer Research, 73
E. Alba, J. Albanell, J. Haba, A. Barnadas, L. Calvo, P. Sánchez‐Rovira, M. Ramos, F. Rojo, O. Burgués, E. Carrasco, R. Caballero, I. Porras, A. Tibau, M. Cámara, A. Lluch (2014)
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trialBritish Journal of Cancer, 110
P. Rastogi, S. Anderson, H. Bear, C. Geyer, M. Kahlenberg, A. Robidoux, R. Margolese, J. Hoehn, V. Vogel, S. Dakhil, D. Tamkus, K. King, E. Pajon, Mary Wright, J. Robert, S. Paik, E. Mamounas, N. Wolmark (2008)
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 5
(2013)
update of the initial randomized study population and data of additional patients treated with the same regimen
M. Untch, M. Rezai, S. Loibl, P. Fasching, J. Huober, H. Tesch, I. Bauerfeind, J. Hilfrich, H. Eidtmann, B. Gerber, C. Hanusch, T. Kühn, A. Bois, J. Blohmer, C. Thomssen, S. Costa, C. Jackisch, M. Kaufmann, K. Mehta, G. Minckwitz (2010)
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 12
Neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2)-positive breast cancer is exactly the paradigm of targeted therapy and a suitable setting to develop and test rapidly novel therapies in early stages. Moreover, neoadjuvant approaches provide a significant source of tumour tissue to identify molecular heterogeneity and potential predictive biomarkers of response. The addition of trastuzumab to primary chemotherapy revolutionized the treatment of this tumour subtype, increasing pathological complete response rate (pCR) that, even with its limitations, has also been shown to be an early marker of survival in HER2-positive disease. HER2-positive breast cancer is a biological heterogeneous disease with different characteristics and clinical outcomes. Multiple promising anti-HER2 drugs with nonoverlapping mechanisms of action have recently been developed. Combined administration of two different HER2-targeted agents, that is, trastuzumab with lapatinib or pertuzumab, and primary chemotherapy shows enhanced antitumour activity, with an increase in pCR to values never reached in the past. Moreover, results of recent studies show that the combination of targeted therapy alone (dual HER2 blockade with or without endocrine therapy) also has activity in a substantial percentage of patients, eradicating HER2-positive tumours without chemotherapy and with a favourable toxicity profile. It is still necessary to be able to select the appropriate group of patients who can avoid chemotherapy (approximately 25%), and to establish robust predictive biomarkers of response or resistance to the anti-HER2 approach. Neoadjuvant therapy represents an enormous step forward in HER2-positive breast cancer. The results of the most relevant neoadjuvant studies and latest evidence are described in this review, though new questions have emerged.
Therapeutic Advances in Medical Oncology – SAGE
Published: May 23, 2014
Keywords: dual HER2 blockade,early breast cancer,HER2 positive,neoadjuvant therapy,pathological complete response,predictive biomarkers
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.